Applications of Metabolomics in Cancer Studies

Armitage, Emily G.; Ciborowski, Michał

doi:10.1007/978-3-319-47656-8_9

Cited by 78 publications

(60 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metabolomics methodology aims to identify and estimate the relative changes in the abundance of endogenous metabolites in health and disease, thus supporting the identification of biomarkers and potential targets for the development of new therapeutics [ 35 – 37 ]. Given the role of the pancreas as a major metabolic organ, it is reasonable to assume that the identification, characterization and validation of novel disease stratification criteria based on metabolic profiles offers a strategic advantage for PC research [ 38 – 47 ].…”

Section: Introductionmentioning

confidence: 99%

Metabolomic biomarkers of pancreatic cancer: a meta-analysis study

Mehta

Menon

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Pancreatic cancer (PC) is an aggressive disease with high mortality rates, however, there is no blood test for early detection and diagnosis of this disease. Several research groups have reported on metabolomics based clinical investigations to identify biomarkers of PC, however there is a lack of a centralized metabolite biomarker repository that can be used for meta-analysis and biomarker validation. Furthermore, since the incidence of PC is associated with metabolic syndrome and Type 2 diabetes mellitus (T2DM), there is a need to uncouple these common metabolic dysregulations that may otherwise diminish the clinical utility of metabolomic biosignatures. Here, we attempted to externally replicate proposed metabolite biomarkers of PC reported by several other groups in an independent group of PC subjects. Our study design included a T2DM cohort that was used as a non-cancer control and a separate cohort diagnosed with colorectal cancer (CRC), as a cancer disease control to eliminate possible generic biomarkers of cancer. We used targeted mass spectrometry for quantitation of literature-curated metabolite markers and identified a biomarker panel that discriminates between normal controls (NC) and PC patients with high accuracy. Further evaluation of our model with CRC, however, showed a drop in specificity for the PC biomarker panel. Taken together, our study underscores the need for a more robust study design for cancer biomarker studies so as to maximize the translational value and clinical implementation.

show abstract

Section: Introductionmentioning

confidence: 99%

Metabolomic biomarkers of pancreatic cancer: a meta-analysis study

Mehta

Menon

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Metabolomics was applied in this study to compare tumor tissues and adjacent healthy skin tissues to explore the disease progression of CTCL. Metabolomics analyses have concerned a range of cancers including lung, colorectal, bladder, breast, gastric, oesophageal, and thyroid, among others, for discovery of biomarkers and personal medicine . For example, the glutamate‐to‐glutamine ratio represents new biomarker that was increased in 88% of hormone receptor negative (HR−) tumors and 56% of hormone receptor positive (HR+) tumors compared to normal breast tissues .…”

Section: Discussionmentioning

confidence: 99%

Accelerated, untargeted metabolomics analysis of cutaneous T‐cell lymphoma reveals metabolic shifts in plasma and tumor adjacent skins of xenograft mice

Shen

Kang

et al. 2018

J Mass Spectrom

View full text Add to dashboard Cite

Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of skin-homing T-cell neoplasms. Clinical management is stage based but diagnosis and prognosis could be extremely challenging. The presented study aims to explore the metabolic profiling of CTCL by an accelerated untargeted metabolomics data analysis tool "Mummichog" to facilitate the discoveries of potential biomarkers for clinical early stage diagnosis, prognosis, and treatments in CTCL. Ultra high-performance liquid chromatography-quadrupole time-of-flight-based untargeted metabolomics were conducted on the skin and plasma of CTCL mice. It showed that the metabolism of skin changed greatly versus control samples in the development of CTCL. Increased l-glutamate and decreased adenosine monophosphate were the most essential metabolic features of CTCL tumor and tumor adjacent skins. Unique metabolism changes in tumor adjacent non-involved skin tissues (ANIT) occurred in the progress of carcinogenesis, including upregulated cytidine-5'-triphosphate, aberrant biosynthesis of prostaglandins, pyrimidine, mevalonate pathway, and tryptophan degradation. Sharply elevated 5-phospho-α-d-ribose 1-diphosphate (PRPP) marked the final state of tumor in CTCL. In the plasma, systematic shifts in corticosterone, sphingolipid, and ceramide metabolism were found. These uncovered aberrant metabolites and metabolic pathways suggested that the metabolic reprogramming of PRPP in tumor tissues may cause the disturbance of cytidine and uridine metabolic homeostasis in ANIT. Accumulative cytidine-5'-triphosphate in ANIT may exert positive feedback on the PRPP level and leads to CTCL further development. In addition, the accelerated data analysis tool "Mummichog" showed good practicability and can be widely used in high-resolution liquid chromatography mass spectrometry-based untargeted metabolomics.

show abstract

“…In accordance with the holistic perspective of Chinese medicines, metabolomics opens up a unique and novel insight into efficacy evaluation and action mechanism exploration of Chinese medicines as adjuvant therapies for cancer prevention and treatment. Increasing excellent reviews have been focused on the application of metabolomics in the metabolic changes and the possible underlying mechanisms behind these alterations in the pathogenesis of different kinds of cancer [33][34][35]. Little reviews have been highlighted on the metabolism-based anticancer therapies.…”

Section: Chinese Medicines and Cancer Treatmentmentioning

confidence: 99%

Chinese Medicines for Cancer Treatment from the Metabolomics Perspective

Guo¹,

Tan²,

Wang³

et al. 2020

Metabolomics - New Insights Into Biology and Medicine

View full text Add to dashboard Cite

Cancer is one of the most prevalent diseases all over the world with poor prognosis and the development of novel therapeutic strategies is still urgently needed. The large amount of successful experiences in fighting against cancer-like diseases with Chinese medicine has suggested it as a great source of alternative treatments to human cancers. Cancer cells have been shown to own a predominantly unique metabolic phenotype to facilitate their rapid proliferation. Metabolic reprogramming is a remarkable hallmark of cancer and therapies targeting cancer metabolism can be highly specific and effective. Based on the sophisticated study of small molecule metabolites, metabolomics can provide us valuable information on dynamically metabolic responses of living systems to certain environmental condition. In this chapter, we systematically reviewed recent studies on metabolism-targeting anticancer therapies based on metabolomics in terms of glucose, lipid, amino acid, and nucleotide metabolisms and other altered metabolisms, with special emphasis on the potential of metabolic treatment with pure compounds, herb extracts, and formulations from Chinese medicines. The trends of future development of metabolism-targeting anticancer therapies were also discussed. Overall, the elucidation of the underlying molecular mechanism of metabolism-targeting pharmacologic therapies will provide us a new insight to develop novel therapeutics for cancer treatment.

show abstract

Applications of Metabolomics in Cancer Studies

Cited by 78 publications

References 116 publications

Metabolomic biomarkers of pancreatic cancer: a meta-analysis study

Metabolomic biomarkers of pancreatic cancer: a meta-analysis study

Accelerated, untargeted metabolomics analysis of cutaneous T‐cell lymphoma reveals metabolic shifts in plasma and tumor adjacent skins of xenograft mice

Chinese Medicines for Cancer Treatment from the Metabolomics Perspective

Contact Info

Product

Resources

About